14,15-epoxy-5,8,11-eicosatrienoic acid

Subscribe to Selected New Research on 14,15-epoxy-5,8,11-eicosatrienoic acid

10 relevant articles (1 outcomes, 0 trials/studies) found for this Bio-Agent

Description: RN given refers to cpd without isomeric designation

Also Known As:

14,15-EET; 14,15-epoxy-5,8,11-eicosatrienoic acid, (2alpha(5Z,8Z,11Z),3alpha)-isomer; 14,15-epoxyeicosatrienoic acid; 14,15-oxido-5,8,11-eicosatrienoic acid

Relationship Network

Bio-Agent Context: Research Results

Lipids: 13324

Fatty Acids: 4669

Unsaturated Fatty Acids: 2223

Eicosanoids: 1154

8,11,14-Eicosatrienoic Acid: 76

14,15-epoxy-5,8,11-eicosatrienoic acid: 10

Related Diseases

1.	Ischemia 05/09/1997 - "Importantly, neither 14,15-epoxyeicosatrienoic acid nor 19-hydroxyeicosatetraenoic acid significantly improved functional recovery following global ischemia, demonstrating the specificity of the biological effect for the 11, 12-epoxyeicosatrienoic acid regioisomer" 11/01/2008 - "14,15-EET, the main substrate for sEH, was administered intravenously 15 min before LCA occlusion or during ischemia 5 min before reperfusion" 03/01/2007 - "The protective effect of pretreatment with 11,12- and 14,15-EETs was completely abolished (61.9+/-0.7%, 58.6+/-3.1%, HMR; 63.3+/-1.2%, 63.2+/-2.5%, 5-HD) in the presence of the selective sarcK(ATP) channel antagonist, HMR 1098 (6 mg/kg, iv) or the selective mitoK(ATP) channel antagonist, 5-HD (10 mg/kg, iv) given 10 min after 11,12- or 14,15-EET administration but 5 min prior to index ischemia" Order ALL the reference details at left...
2.	Reperfusion Injury 10/01/2005 - "On the other hand, a group of regioisomers resulting from the epoxidation of AA, including 5,6-, 8,9-, 11,12- and 14,15-epoxyeicosatrienoic acid (EETs), have been shown to reduce ischemic and/or reperfusion injury in the heart and vasculature" 11/01/2008 - "Strategies to increase 14,15-EET, including sEH inactivation, may represent a novel therapeutic approach for cardioprotection against myocardial ischemia-reperfusion injury." Order ALL the reference details at left...
3.	Coronary Occlusion 08/01/2006 - "We demonstrate that two major regioisomers of CYP epoxygenases, 11,12-EET and 14,15-EET, significantly reduced IS in dogs compared to control (22.1 +/- 1.8%), whether administered 15 min before 60 min of coronary occlusion (6.4 +/- 1.9%, 11,12-EET; and 8.4 +/- 2.4%, 14.15-EET) or 5 min before 3 h of reperfusion (8.8 +/- 2.1%, 11,12-EET; and 9.7 +/- 1.4%, 14,15-EET)" Order ALL the reference details at left...
4.	Atherosclerosis (Atheroma) 02/28/1990 - "Thus, 14,15-EET may play a substantial role in inflammation and/or atherogenesis by inducing monocyte attachment to EC." Order ALL the reference details at left...
5.	Myocardial Ischemia (Ischemic Heart Diseases) 11/01/2008 - "Strategies to increase 14,15-EET, including sEH inactivation, may represent a novel therapeutic approach for cardioprotection against myocardial ischemia-reperfusion injury." Order ALL the reference details at left...

Related Drugs and Biologics

1.	11,12-epoxy-5,8,14-eicosatrienoic acid
2.	Adenosine Triphosphate (ATP)
3.	HMR 1098
4.	mitochondrial K(ATP) channel
5.	14,15-dihydroxyeicosatrienoic acid
6.	8,9-epoxyeicosatrienoic acid

Best Treatments:
Research Summary Report
on Ischemia

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2709 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>